Argent Biopharma Limited has released a press release.
Cimetra patent submitted to european ip office
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- Further findings on artemic as anti-inflammatory agent
- $1M order for artemic rescue from swiss pharmacan
- Artemic submitted to health canada
- March quarterly activity and cashflow report
- Mgc pharma to acquire medical research company medicanl
Later from Argent Biopharma
- Mgc pharma 2021 clinical trials program update
- Cannepil available for free dispensing in ireland
- 1St patient recruited into cimetra phase 3 clinical trial
- Patent application lodged for novel drug delivery system
- Mgc pharma executes US$24M US supply agreement
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma